Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C

BACKGROUND: Cost-benefit analyses are crucial to inform treatment policies, particularly when the cost of patented drugs is very high. The cost of patented drugs is the limiting factor in hepatitis C treatment. However, hepatitis C drug costs are expected to fall following patent expiration, due to...

Descripción completa

Detalles Bibliográficos
Autor principal: Heath, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159796/
https://www.ncbi.nlm.nih.gov/pubmed/30288069
http://dx.doi.org/10.2147/CEOR.S171248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159796/
https://www.ncbi.nlm.nih.gov/pubmed/30288069
http://dx.doi.org/10.2147/CEOR.S171248

Ejemplares similares